PAMP
VRDN icon

Polar Asset Management Partners’s Viridian Therapeutics VRDN Stock Holding History

Polar Asset Management Partners’s Portfolio VRDN Stock Details VRDN Fund Activity
Bought
Maintained
Sold
Quarter Market Value Status Shares Change in
Stake 		Trade Value Portfolio Weight Portfolio Position
2024
Q4 		– Sell
-163,000
Closed -$3.71M – 798
2024
Q3 		$3.71M Buy
163,000
+53,100
+48% +$868K 0.08% 243
2024
Q2 		$1.43M Sell
109,900
-1,500
-1% -$20.8K 0.03% 362
2024
Q1 		$1.95M Sell
111,400
-48,300
-30% -$936K 0.03% 364
2023
Q4 		$3.48M Buy
159,700
+83,100
+108% +$1.31M 0.06% 279
2023
Q3 		$1.18M Buy
+76,600
New +$1.46M 0.03% 437
2023
Q1 		– Sell
-204,600
Closed -$5.98M – 1168
2022
Q4 		$5.98M Sell
204,600
-106,200
-34% -$2.45M 0.07% 378
2022
Q3 		$6.38M Buy
310,800
+251,100
+421% +$4.51M 0.08% 394
2022
Q2 		$691K Hold
59,700
– – 0.01% 784
2022
Q1 		$1.1M Hold
59,700
– – 0.01% 678
2021
Q4 		$1.18M Hold
59,700
– – 0.01% 689
2021
Q3 		$982K Buy
+59,700
New +$876K 0.01% 686

Other funds holding VRDN

Fidelity Investments
Fidelity Investments Boston, Massachusetts $2.3T AUM 54.33% 1-Year Est. Return
BlackRock
BlackRock New York $6.73T AUM 46.02% 1-Year Est. Return
Vanguard Group
Vanguard Group Malvern, Pennsylvania $6.9T AUM 27.45% 1-Year Est. Return
DTC
Deep Track Capital Greenwich, Connecticut $6.87B AUM 205.24% 1-Year Est. Return
VA
VR Adviser New York $3.3B AUM 525.74% 1-Year Est. Return
State Street
State Street Boston, Massachusetts $3.38T AUM 44.17% 1-Year Est. Return
FFM
Fairmount Funds Management West Conshohocken, Pennsylvania $1.51B AUM 546.08% 1-Year Est. Return
KCM
Kynam Capital Management Princeton, New Jersey $1.81B AUM 192.15% 1-Year Est. Return
TCM
Tang Capital Management San Diego, California $2.2B AUM 156.35% 1-Year Est. Return
CC
Commodore Capital New York $1.68B AUM 375.52% 1-Year Est. Return

Polar Asset Management Partners's VRDN Position: Q4 2024 in Review

Polar Asset Management Partners sold out of Viridian Therapeutics (VRDN) in Q4 2024, closing a stake of 163,000 shares — an estimated $3.71M sold.

Polar Asset Management Partners first reported a position in VRDN in Q3 2021 and held it in 11 quarters. The position peaked at $6.38M in Q3 2022. 178 funds tracked by Wall St. Rank hold VRDN as of Q4 2024.

  • Polar Asset Management Partners reported no remaining Viridian Therapeutics position as of Q4 2024 after selling out during the quarter.
  • Polar Asset Management Partners sold 163,000 Viridian Therapeutics shares in Q4 2024, an estimated $3.71M.
  • Polar Asset Management Partners first reported a position in Viridian Therapeutics in Q3 2021 and held it in 11 quarters.
  • Polar Asset Management Partners's Viridian Therapeutics position peaked at $6.38M in Q3 2022.
  • 178 funds tracked by Wall St. Rank held Viridian Therapeutics as of Q4 2024.

Based on Polar Asset Management Partners's 13F filing for Q4 2024, filed 14 Feb 2025.